Status: Contract Extension
Date: 07/14/2021
Player: Teodors Blugers (F)
From: Pittsburgh Penguins
To: Pittsburgh Penguins
Information: 2 years
Source: https://www.nhl.com/penguins/news/penguins-re-sign-forward-teddy-blueger-to-a-two-year-contract/c-325656350
Status: Confirmed Transaction
Date: 07/14/2021
Player: Tobias Degvold (D)
From: Storhamar U21
To: Manglerud
Source: https://www.mshockeyelite.no/artikel/ag83akr3m-335md/tobias-degvold
Status: Contract Extension
Date: 07/14/2021
Player: Fabian Bohman (F)
From: Åseda IF
To: Åseda IF
Source: https://www.instagram.com/p/CRPLMgLMhkZ/
Status: Confirmed Transaction
Date: 07/14/2021
Player: Aleksis Leskinen (F)
From: HCIK
To: Grums IK
Source: https://www.svenskalag.se/grumsik/nyheter/1653106/finsk-forward-klar
Status: Confirmed Transaction
Date: 07/14/2021
Player: Kevin Berglund (F)
To: HC Flyers
Source: https://www.facebook.com/KarlskogaHC/posts/4364790966912702
Status: Confirmed Transaction
Date: 07/14/2021
Player: Pavils Galsons (F)
From: Flemingsbergs IK
To: Åseda IF
Source: https://www.instagram.com/p/CRUCteos58a/
Status: Confirmed Transaction
Date: 07/14/2021
Player: Zikmund Mróz (D)
From: Lebanon Valley College
To: Lindlövens IF
Source: https://www.lindloven.com/lindlovenalag/nyheter/1653110/nyforvarv-tjeckisk-back-ansluter
Status: Confirmed Transaction
Date: 07/14/2021
Player: Dennis Westergård (G)
From: Tønsberg Vikings
To: Vännäs HC
Source: https://www.facebook.com/vannashockey/posts/3167490256812579
Status: Confirmed Transaction
Date: 07/14/2021
Player: Filiph Laine (F)
From: SK Lejon
To: Vännäs HC
Source: https://www.facebook.com/vannashockey/posts/3167471176814487
Status: Confirmed Transaction
Date: 07/14/2021
Player: Simon Söderberg (D)
From: SK Lejon
To: Vännäs HC
Source: https://www.facebook.com/vannashockey/posts/3167471176814487
Status: Confirmed Transaction
Date: 07/14/2021
Player: Christoffer Gozzi (F)
From: Väsby IK
To: Grüner
Source: https://twitter.com/GrunerHockey/status/1415371085802004481
Status: Contract Extension
Date: 07/14/2021
Player: Magnus Isaksson (F)
From: Piteå HC
To: Piteå HC
Source: https://www.facebook.com/piteahc/posts/4037416506313042
HFC is leading the way in college affordability and innovation, with the help of government and non-profit partners.
Alba Zari writes about searching for her biological father in her recent project, 'The Y', and her current work investigating the cult she was born in to.
Our poll tracker shows who might be next into the chancellery
The government’s decision to allow only the fully vaccinated to enter restaurants, bars, trains and other spaces has caused a spike in inoculations
Blame stimulus cheques, a shortage of new vehicles and rising demand for rental cars
The main intention of this project was to enhance and exaggerate the ‘as found’ spatial condition of the site with as little articulation of spatial gestures as necessary to house an architectural practice.
Kevin Mulleady and Jason Aryeh attempted to back a slate of candidates for the Phoenixus Board of Directors but failed as shareholders overwhelmingly supported the current board.
The new CEO of Freenome has a talent for “making his own weather.” That’s a phrase he heard often growing up in Rapid City, South Dakota and, when applied to his life and career, comes down to assessing himself accurately and looking for opportunities to contribute.
Thermo Fisher Scientific has launched a new collaborative unit that aims to standardize the metabolomics community's efforts as it engages in more large-scale cohort studies and clinical research.
In its 2Q2021 Clinical Report, BioSpace highlights drugs that were greenlit for clinical studies, faced clinical and regulatory hurdles and some who saw regulatory wins.
More biopharma companies race toward the Nasdaq this week, while a few rake in cash via private funding rounds.
The medication, should it be approved for use, will be squirted into the nasal passages, ensuring absorption into the body and reverses the overdose effects.
In an interview with BioSpace, CEO Victoria Richon expressed her excitement about investor support and developing novel, first-in-class treatments.
